Dr. Michael Morris, MD – New York, NY

Overview of Dr. Morris

Dr. Michael Morris is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. He received his medical degree from Icahn School of Medicine at Mount Sinai and has been in practice 23 years. He specializes in genitourinary oncology and his clinical and research focus is on high risk, recurrent, and metastatic prostate cancer, regarding drug, imaging, and biomarker development.

Education & Training

• Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1997 - 2000

• New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1994 - 1997

• Icahn School of Medicine at Mount SinaiClass of 1994

Certifications & Licensure

• FL State Medical License 2021 - Present

• NJ State Medical License 2019 - 2025

• NY State Medical License 1996 - 2025

• American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

• Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with ...

  Nixon, A., Liu, Y., Yang, Q., Luo, B., Starr, M., Brady, J., Kelly, W., Halabi, S., Beltran, H., Morris, M., George, D., Armstrong, A.> ;Prostate Cancer and Prostatic Diseases. 2024 Feb 12

• Design Considerations in the PSMAfore Trial.

  Sartor, O., Fizazi, K., Herrmann, K., Morris, M.> ;Journal of Nuclear Medicine. 2024 Feb 1

• PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (A...

  Aggarwal, R., Heller, G., Hillman, D., Xiao, H., Picus, J., Taplin, M., Dorff, T., Appleman, L., Weckstein, D., Patnaik, A., Bryce, A., Shevrin, D., Mohler, J., Anders...> ;Journal of Clinical Oncology. 2024 Jan 23
• Join now to see all

Press Mentions

• Transforming Cancer Clinical Trials for Better, Faster ResultsApril 14th, 2023

• PSMA PET Academy - Case Discussion: PSMA for Biochemical Recurrence and SRT Planning: Early Biochemical Relapse in Patients - Jeremie Calais, Michael Morris, & Alberto BrigantiMarch 17th, 2023

• NIH Awards $23 Million for Telehealth OncologyAugust 30th, 2022

• Join now to see all

Professional Memberships

Hospital Affiliations

Insurance Accepted

• Aetna Choice POS II
  Aetna HMO
  BCBS Blue Card PPO
  CIGNA HMO
  CIGNA Open Access
  CIGNA PPO
  Empire BCBS HMO
  Empire BCBS PPO
  Great West PPO
  Humana ChoiceCare Network PPO
  

  Multiplan PHCS PPO
  Multiplan PPO
  MVP Healthcare PPO
  Oxford Health Freedom
  Oxford Health Liberty
  QualCare HMO
  QualCare PPO
  United Healthcare - Direct Choice Plus POS
  United Healthcare - Direct Options PPO
  

• Please verify your coverage with the provider's office directly when scheduling an appointment